Irritable bowel syndrome (IBS) is one of the most common functional bowel disorder worldwide (Clin Gastroenterol Hepatol 2012;10:712-721). The diagnosis is based on a patient reporting a specific combination of symptoms, as defined by the Rome criteria: abdominal pain, which is related to defecation, associated with a change in stool frequency or form (Gastroenterology 2016;150:1393-1407). IBS is further sub-grouped dependent on predominant stool form, be that diarrhea (IBS-D), constipation (IBS-C), or mixed stool pattern (IBS-M). Patients with IBS-D may be particularly debilitated by urgency and the fear of incontinence, reporting poor quality of life as a result, (Health Qual Life Outcomes 2017;15:35) and may resort to using drugs such as loperamide in an attempt to control their stool frequency. Unfortunately, patients frequently report dissatisfaction with this strategy, for which good quality evidence is lacking (Am J Gastroenterol 2018;113 (Suppl 2):1-18).

中文翻译：

---

预测腹泻型肠易激综合征对利福昔明的反应：答案是否随风而来？

肠易激综合症（IBS）是全世界最常见的功能性肠病之一（Castro Gastroenterol Hepatol 2012; 10：712-721）。该诊断基于患者报告的特定症状组合，如罗马标准所定义：与排便有关的腹痛与大便频率或形式的变化相关（Gastroenterology 2016; 150：1393-1407）。IBS根据主要的粪便形式进一步细分，例如腹泻（IBS-D），便秘（IBS-C）或混合粪便模式（IBS-M）。IBS-D患者可能由于紧迫感和对大小便失禁的恐惧而特别虚弱，结果报告生活质量较差（《健康质量生活成果》 2017年； 15：35），并可能诉诸于使用洛哌丁胺等药物来试图控制他们的大便频率。不幸，